These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28454726)

  • 1. Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib.
    Vanwynsberghe H; Verbeke X; Coolen J; Van Cutsem E
    Clin Colorectal Cancer; 2017 Dec; 16(4):377-380. PubMed ID: 28454726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
    BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular assessment of regorafenib monotherapy.
    Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
    Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
    Masuishi T; Taniguchi H; Hamauchi S; Komori A; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
    Clin Colorectal Cancer; 2017 Jun; 16(2):e15-e22. PubMed ID: 27670892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
    Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
    J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
    Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
    BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
    Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis.
    Reginelli A; Clemente A; Cardone C; Urraro F; Izzo A; Martinelli E; Troiani T; Ciardiello F; Brunese L; Cappabianca S
    Future Oncol; 2018 Dec; 14(28):2905-2913. PubMed ID: 29433345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
    Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
    Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
    Komori A; Taniguchi H; Hamauchi S; Masuishi T; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
    Oncology; 2017; 93(5):329-335. PubMed ID: 28866662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
    Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
    J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
    Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
    Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
    Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.
    Rosati G; Del Gaudio N; Scarano E; Cifarelli RA; Altucci L; Bilancia D
    Medicine (Baltimore); 2018 Jun; 97(25):e11178. PubMed ID: 29924031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603).
    Oki E; Kawahira M; Kusumoto T; Yuki S; Hatanaka K; Kobayashi Y; Nishie A; Kawanami S; Makiyama A; Saeki H; Sakamoto S; Komatsu Y; Shimokawa M; Mori M; Esaki T
    Oncology; 2020; 98(10):719-726. PubMed ID: 32640458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
    Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
    Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
    Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence.
    Cervantes A; Tabernero J; Garcia-Carbonero R; Sastre J; Feliu J; Carmen Guillén-Ponce ; Paredes BG; Carral A; Muñoz J
    Future Oncol; 2024; 20(20):1401-1413. PubMed ID: 38861286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.